How much is too much? Outcomes in patients using high-dose insulin glargine

International Journal of Clinical Practice

Volumn 70, Issue 1, 2016, Pages 56-65

  Reid, T ^a   Gao, L ^b   Gill, J ^c   Stuhr, A ^c   Traylor, L ^c   Vlajnic, A ^c   Rhinehart, A ^d  

^a Mercy Diabetes Center   (United States)

^b Analysta Inc   (United States)

^c SANOFI   (France)

^d Johnston Memorial Diabetes Care Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; METFORMIN; SULFONYLUREA; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; BODY WEIGHT; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DIABETIC PATIENT; DIET RESTRICTION; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG MEGADOSE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT INFORMATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFERENCE VALUE; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT GAIN; ADVERSE EFFECTS; AGED; BLOOD; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM; MIDDLE AGED;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN GLARGINE; MALE; METFORMIN; MIDDLE AGED; SULFONYLUREA COMPOUNDS; WEIGHT GAIN;

EID: 84955296052     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12747     Document Type: Article

References (37)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al., Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38: 140-9.
2. Garber AJ, Abrahamson MJ, Barzilay JI, et al., AACE comprehensive diabetes management algorithm 2013. Endocr Pract 2013; 19: 327-36.
3. Stark Casagrande S, Fradkin JE, Saydah SH, et al., The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care 2013; 36: 2271-9.
4. Mata-Cases M, Benito-Badorrey B, Roura-Olmeda P, et al., Clinical inertia in the treatment of hyperglycemia in type 2 diabetes patients in primary care. Curr Med Res Opin 2013; 29: 1495-502.
5. Reach G,. Clinical inertia, uncertainty and individualized guidelines. Diabetes Metab 2014; 40: 241-5.
6. Khunti K, Wolden ML, Thorsted BL, et al., Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care 2013; 36: 3411-7.
7. Aschner P, Chan J, Owens DR, et al., Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet 2012; 379: 2262-9.
8. Meneghini LF, Traylor L, Schwartz SL,. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus. Endocr Pract 2010; 16: 588-99.
9. Swinnen SG, Dain MP, Aronson R, et al., A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care 2010; 33: 1176-8.
10. HOE901-4022, data on file. ClinicalTrials.gov identifier: NCT00046462.
11. Gerstein HC, Yale JF, Harris SB, et al., A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 2006; 23: 736-42.
12. Fritsche A, Schweitzer MA, Häring HU, et al., Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003; 138: 952-9.
13. Standl E, Maxeiner S, Raptis S, et al., Good glycemic control with flexibility in timing of basal insulin supply: a 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride. Diabetes Care 2005; 28: 419-20.
14. Eliaschewitz FG, Calvo C, Valbuena H, et al., Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Arch Med Res 2006; 37: 495-501.
15. Riddle MC, Rosenstock J, Gerich J, et al., The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-6.
16. Rosenstock J, Sugimoto D, Strange P, et al., Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 2006; 29: 554-9.
17. HOE901-4021, data on file. ClinicalTrials.gov identifier: NCT01336751.
18. Janka HU, Plewe G, Riddle MC, et al., Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005; 28: 254-9.
19. Bretzel RG, Nuber U, Landgraf W, et al., Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008; 371: 1073-84.
20. Yki-Järvinen H, Juurinen L, Alvarsson M, et al., Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care 2007; 30: 1364-9.
21. Blicklé JF, Hancu N, Piletic M, et al., Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study. Diabetes Obes Metab 2009; 11: 379-86.
22. DeVries JH, Meneghini L, Barnett AH, et al., A patient-level analysis of efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine added to oral antidiabetes agents in people with type 2 diabetes. Eur Endocrinol 2014; 10: 23-30.
23. Monnier L, Lapinski H, Colette C,. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003; 26: 881-5.
24. Riddle M, Umpierrez G, DiGenio A, et al., Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care 2011; 34: 2508-14.
25. Lankisch MR, Ferlinz KC, Leahy JL, et al., Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes Obes Metab 2008; 10: 1178-85.
26. Fritsche A, Larbig M, Owens D, et al., Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study. Diabetes Obes Metab 2010; 12: 115-23.
27. Meneghini L, Mersebach H, Kumar S, et al., A comparison of two intensification regimens with rapid-acting insulin aspart in type 2 diabetes inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized study. Endocr Pract 2011; 17: 727-36.
28. Del Prato S, Nicolucci A, Lovagnini-Scher AC, et al., Telecare provides comparable efficacy to conventional self-monitored blood glucose in patients with type 2 diabetes titrating one injection of insulin glulisine-the ELEONOR study. Diabetes Technol Ther 2012; 14: 175-82.
29. Raccah D, Haak TJ, Huet D, et al., Comparison of stepwise addition of prandial insulin to a basal-bolus regimen when basal insulin is insufficient for glycaemic control in type 2 diabetes: results of the OSIRIS study. Diabetes Metab 2012; 38: 507-14.
30. Buse JB, Bergenstal RM, Glass LC, et al., Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011; 154: 103-12.
31. Rosenstock J, Fonseca VA, Gross JL, et al., Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. Diabetes Care 2014; 37: 2317-25.
32. Seino Y, Min KW, Niemoeller E, et al., Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab 2012; 14: 910-7.
33. Riddle MC, Aronson R, Home P, et al., Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 2013; 36: 2489-96.
34. Riddle MC, Forst T, Aronson R, et al., Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care 2013; 36: 2497-503.
35. Vilsbøll T, Rosenstock J, Yki-Järvinen H, et al., Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010; 12: 167-77.
36. Neumiller JJ,. Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Drugs Context 2014. doi: 10.7573/dic.212262.
37. Nauck MA,. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther 2014; 8: 1335-80.